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Abstract 
Adipose tissue secretes many adipokines that regulate impor-
tant physiological functions. Growing studies have highlighted
that these bioactive molecules may contribute to the development
of metabolic and cardiovascular diseases. Adipokines exert sys-
temic metabolic effects and independent activity on numerous
cells of the cardiovascular system, including cardiomyocytes and
vascular cell walls. Adiponectin shows anti-inflammatory and
anti-atherosclerotic activity on blood vessels. Conversely, resistin
is endowed with pro-inflammatory effects and stimulates the pro-
liferation of smooth muscle cells, thus promoting the development
of atherosclerotic plaque. Leptin plays an important role in cardiac
remodeling and blood pressure regulation through the activation
of the sympathetic system. Obesity is a pathological condition
associated with hypertrophy of white adipose tissue, which stimu-
lates the production of pro-inflammatory adipokines while, it
reduces the production of anti-inflammatory adipokines. The del-
icate balance among the production of pro-and anti-inflammatory
molecules generated by adipose tissue affects, not only the devel-
opment of metabolic complications associated with obesity, but
also the onset and progression of atherosclerosis. Therefore,
adipokines may be regarded as potential agents of clinical interest
in the treatment of a wide range of metabolic disorders and as
potential biomarkers useful for early detection of metabolic, car-
diovascular and inflammatory diseases.
Introduction
Adipose Tissue (AT) is a an organ whose cellular composi-
tion varies according to age, gender and tissue distribution.1 For
many decades it has been considered as a passive organ that
functioned, under conditions of excess energy intake, only as
lipid storage depot, to provide energy-rich substrates needed by
other tissues.2 Actually, AT it is recognized as a metabolically
active organ, having endocrine and secretory functions, which
synthesizes and secretes bioactive molecules such as adipocy-
tokines.3-5 These molecules contribute to regulate various phys-
iological functions such as food intake, insulin sensitivity and
inflammatory processes.6 In mammals there are two different
types of AT, e.g. white and brown tissue, which have different
morphology and function. In humans, Brown Adipose Tissue
(BAT) is present in infants and is less represented in adults.
Brown adipocytes are smaller than white adipocytes. The main
function of BAT consists in heat production (thermogenesis),
through the oxidization of fatty acids present inside the
adipocyte.3,4,7 BAT takes the name by its colour, due to the pres-
ence of intense vascularization and the wide content of mito-
chondria.8,9 On the other hand, White Adipose Tissue (WAT) is
widely distributed throughout the body. It is mainly present in
the dermis and in the subcutaneous region of the hollow organs
and abdominal and mediastinal cavities. WAT has the function of
mechanical cushion, reduction of trauma and allows the sliding
of muscles filaments maintaining their integrity.3,7 Furthermore,
WAT acts as a thermal insulator.4 It accumulates triglycerides,
thus providing energy in the form of fatty acids.9 WAT represents
the largest endocrine organ in humans. It has been shown to
secrete numerous hormones, growth factors, enzymes,
cytokines, complement factors and matrix proteins involved in
the regulation of different physiological processes, including
food intake, energy consumption, metabolic homeostasis, immu-
nity and blood pressure.10,11 AT induce its effects through
endocrine, paracrine and autocrine signals.1,12 The endocrine
functions of WAT were first hypothesized following the early
observations showing that it influenced steroids conversion, and
later in 1994 following the identification of leptin.4,7
Correspondence: Marco Giammanco, Department of Surgical,
Oncological and Oral Sciences, University of Palermo, Italy. 
E-mail: marco.giammanco@unipa.it
Key words: Adipokines; adipose tissue; metabolic syndrome; obesity;
cardiovascular disease.
Conflict of interest: The authors declare no potential conflict of interest. 
Received for publication: 23 February 2020.
Accepted for publication: 6 March 2020.
©Copyright: the Author(s), 2020
Licensee PAGEPress, Italy
Journal of Biological Research 2020; 93:8915
doi:10.4081/jbr.2020.8915
This article is distributed under the terms of the Creative Commons
Attribution Noncommercial License (by-nc 4.0) which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
[Journal of Biological Research 2020; 93:8915] [page 145]
Journal of Biological Research 2020; volume 93:8915
Adipokines in obesity and metabolic diseases
Marco Giammanco,1 Herbert R. Marini,2 Socrate Pallio,2 Manfredi Marco Giammanco,3
Giovanni Tomasello,4 Francesco Carini,4 Fabio Venturella,5 Gaetano Leto,6 Maurizio La Guardia5
1Department of Surgical, Oncological and Oral Sciences, University of Palermo; 2Department of Clinical and
Experimental Medicine, University of Messina; 3Department Department of Human Pathology in Adulthood and
Childhood ''G. Barresi'', Medical School University of Messina; 4Departments of Biomedicine, Neuroscience and
Advanced Diagnostics; 5Department of Biological Chemical and Pharmaceutical Sciences and Technologies;










[page 146]                                                [Journal of Biological Research 2020; 93:8915]                              
Metabolic syndrome
The metabolic syndrome represents a clinical condition char-
acterized by obesity, insulin resistance (decreased ability of the tis-
sues to respond to the action of insulin) and hypertension. It is
often associated with dyslipidaemias and Non-Alcoholic Fatty
Liver Disease (NAFLD) and represents a risk factor for type 2 dia-
betes mellitus and cardiovascular disease.13,14
Obesity, especially abdominal obesity, which is considered a
chronic inflammatory disease, has been shown to play a key role
(Figure 1). The inflammatory condition associated with the meta-
bolic syndrome is characterized by the presence high concentra-
tions of pro-inflammatory molecules, such as C-reactive protein,
TNF-α, Resistin, IL-6, IL-8, visfatin and adiponectin.15 Low levels
of adiponectins has been observed in both adults and children with
metabolic syndrome. On the contrary, higher levels of adiponectins
have been shown to exert a protective function against the onset of
metabolic syndrome.16
Insulin resistance and adipokines
AT is a tissue that responds to the action of insulin which, in
turn, stimulates the accumulation of triglycerides in the AT through
various mechanisms.17 Insulin resistance induced by obesity is
related to an increased secretion of cytokines and bioactive sub-
stances by the AT, and to an increase in macrophages infiltrating
the AT which account for a chronic inflammatory state.13,18-20
These proteins are secreted by adipocytes and cells of the immune
system, and in particular by macrophages. Many of these mole-
cules such as Monocyte Chemoattractant Protein (MCP-1), Tumor
Necrosis Factor-α (TNF-α), interleukin-6 (IL-6), IL-18, leptin,
resistin, Plasminogen Activator Inhibitor (PAI-1), visfatin, Retinol-
Binding Protein-4 (RBP-4) have pro-inflammatory activity, while
others such as adiponectin, Secreted Frizzled-Related Protein-5
(SFRP-5) are anti-inflammatory adipokines.21 TNF-α is a pro-
inflammatory cytokine which can contribute to the pathogenesis of
obesity and insulin resistance.22 In humans, the expression of TNF-
α is increased in obesity and in presence of insulin resistance.
However, the correlation between TNF-α plasma levels and insulin
resistance is relatively weak.22,23 IL-6 is a cytokine associated with
the development of insulin resistance in obesity.24 In humans, 10-
35% of the circulating levels of IL-6 are produced by adipose tis-
sue, and its production increased following hypertrophic enlarge-
ment of adipocytes.25 On the other hand, in vitro and in vivo studies
have shown that IL-6 expression levels are positively associated
with insulin.26 However, the correlation between IL-6 and obesity
or insulin resistance remains controversial. IL-18 is another pro-
inflammatory cytokine produced by AT.27 Circulating levels of IL-
18 are increased in obese subjects and decrease following weight
loss.28 However, further studies are needed to confirm the role of
IL-6 and IL-18.
Leptin
The discovery of leptin as a product of the ob gene in obese
mice dates to 1994.29 Leptin is a protein secreted primarily from
AT. Its plasma levels are increased in subjects with a higher fat
mass. Leptin secretion increases after a meal, due to the increase in
insulin secretion. Leptin is secreted, at lower concentrations, from
placenta, gastric epithelium, bronchial mucosa and mammary
gland. Glucocorticoids, acute infections and pro-inflammatory
cytokines contribute to increasing leptin levels, while exposure to
cold, adrenergic stimulation, Growth Hormone (GH), thyroid hor-
mones, melatonin, cigarette smoking and thiazolidinediones
reduce its circulating levels.11,30-33 Circulating leptin is higher in
women than in men, as a result of inhibition by androgens and
stimulation by estrogens. This hormone plays an important role in
regulating food intake, energy consumption and fertility. In the
hypothalamus, leptin increases the synthesis of the anorexic pep-
tides α-MSH and decreases the synthesis of orexic peptide (NPY),
with a consequent reduction of the appetite.34 In obese subjects, the
circulating levels of the hormone are increased due to the onset of
leptin resistance.35 Furthermore, leptin receptors are expressed in
the central reward processing pathway, These findings suggest that
the reduction of food intake induced by leptin is not only related to
its effect on hypothalamus.36,37 Leptin reduces insulin secretion
and its metabolic effects38-41 while it increases fat oxidation.42
Leptin promotes also apoptosis of adipocytes43-46 and is endowed
with pro-inflammatory effects. Consistent with these findings, lep-
tin has been observed to promote the production of pro-inflamma-
tory cytokines (IL-2 and IFN-γ)47 and contributes to maintaining a
chronic state of inflammation in obese patients.48
Resistin
Resistin is an adipokine secreted by adipocytes that promotes
both inflammation and insulin resistance in mouse models.49 Data
on the correlation between resistin and metabolic disorders in
humans are still controversial. In fact, although, some studies have
reported a close relationship between resistin levels and obesity,
insulin resistance or type 2 diabetes, other studies have highlighted
no association between resistin and insulin resistance.50,51 The cir-
culating levels of resistin are increased in both experimental obese
animals and humans, while they are reduced by rosiglitazone
administration.52,53
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Nicotinamide Phosphoribosyltransferase (NAMPT), also
known as visfatin was initially described as an adipokine secreted
mainly by visceral adipose tissue.54 Subsequent studies in humans
have shown that visfatin is also expressed in other tissues.
However, its insulin-mimetic role appears controversial.55,56
Adiponectin
Adiponectin is an adipokine specifically secreted by adipose
tissue.57 There are three circulating isoforms of adiponectine, e.g.
trimer, hexamer and multimeric complex.58 Two adiponectin
receptors have recently been identified. AdipoR1 is a receptor for
globular adiponectin and is abundantly expressed in skeletal mus-
cle, whereas AdipoR2, a receptor for full-length adiponectin, is
mainly expressed in the liver. Two types of adiponectin receptors
contain seven transmembrane domains have been identified,
namely AdipoR1 which is expressed in skeletal muscle and
AdipoR2 which is expressed in skeletal muscle and liver. The
expression of these receptor results decreased in obesity-related
insulin resistance.59 A member of the cadherin super family, T-cad-
herin, has been identified as a potent receptor for the hexameric
form and for an adiponectin oligomer.60 Adiponectin induces an
increase in insulin sensitivity. This molecule exerts anti-inflamma-
tory and anti-apoptotic functions on various types of cells, and acts
at hypothalamic level as regulator of energy homeostasis. In par-
ticular it increases energy consumption thus causing weight loss.61
The circulating levels of adiponectin are decreased in presence of
metabolic disorders.61 On the other hand, adiponectin expression is
reduced in adipose tissue, in obese subjects and in insulin resistant
subjects compared to lean subjects. Furthermore, this phenomenon
is associated with a reduced insulin sensitivity and a low expres-
sion of TNF-α in the adipose tissue.62 The restoration of proper
adiponectin levels could be of clinical relevance as a new therapeu-
tic approach in the treatment of metabolic disorders associated
with obesity.63 In this context, synthetic orally active agonists of
adiponectin receptors that bind and activate AdipoR1 and AdipoR2
receptors, i.e., the so called AdipoRon, have been challenged on
diabetics and obese mice. The results obtained were like those
observed with adiponectin (i.e., increase in sensitivity and toler-
ance to glucose, reduction of cardiovascular pathologies and can-
cer). In addition, these studies also showed an significant increase
in the life span of mice. However, further studies are needed to bet-
ter define the pharmacological and toxicological profile of these
molecule and their long-term effects.64
Frizzled-related secreted protein- 5
Secreted Frizzled-Related Protein-5 (SFRP-5) is a protein
endowed with insulin sensitizing and anti-inflammatory proper-
ties. It is highly expressed in the AT and exert beneficial effects on
metabolic dysfunctions.65 The results from emerging studies have
highlighted a positive correlation between SFRP-5 levels and car-
bohydrate parameters in healthy and obese subjects. However, fur-
ther investigation is needed to better assess this phenomenon.66
Apelin
Apelin is an adipokine involved in the regulation of glucose
homeostasis.67 The circulating levels of Apelin are increased in
obese patients and in patients with insulin resistance and liver cir-
rhosis.67,68 Conversely, decreased serum levels of Apelin hare
associated with an improved insulin sensitivity, a phenomenon
which does not appear to be associated with a significant weight
loss.68 Experimental in vivo studies in mice, indicate a possible
correlation of Apelin with glucose homeostasis, obesity and related
diseases. However further studies are needed in humans to better
define these effects.
Vaspin
Vaspin is a novel serine protease inhibitor (serpin), with
insulin-sensitizing effect, produced by visceral adipose tissue. It is
also expressed in the hypothalamus, stomach, and pancreatic islets
of rodents.69 The underlying mechanisms which may account for
the improving effect of Vaspin on glucose metabolism remain to be
fully unravelled.70
Nesfatin-1
Nesfatin-1 is an adipokine expressed in central nervous sys-
tem, pituitary gland, stomach, pancreas, testes, and in the adipose
tissue. This new molecule appears to be involved in the regulation
of food intake by acting through a leptin-independent mecha-
nism.71 Experimental observations in mice have shown that
Nesphatin-1 is implicated in adaptive responses to stress condi-
tions and has glucose-dependent insulinotropic effects.72,73
However, studies on humans on the effective physiological role of
this neuro-peptide are still lacking.
Dipeptidyl-dipeptidase-4
Dipeptidyl-Dipeptidase-4 (DPP-4) is an adipokine secreted by
AT.74 DPP-4 circulating levels correlate with the size of adipocytes
and with the inflammatory conditions of the AT.74,75 DPP-4 is pres-
ent in the circulation in overweight and obese subjects76 and may
be responsible of the onset of insulin resistance in adipocytes and
skeletal muscle. It is likely that the metabolic effects of DPP-4
could, at least in part, be related to its function. In fact, this
adipokine is implicated in the degradation of GLP-1, an incretin
that reduces peripheral resistance to insulin. This hypothesis is
supported by the observations that the circulating levels of DPP-4
in insulin-sensitive obese patients are lower compared to those
determined in insulin-resistant obese patients.75 Therefore, the
increased levels of DPP-4 may contribute to obesity and insulin
resistance. The increased activity and concentration of DPP-4 in
obese subjects may be useful as possible a therapeutic target in the
treatment of obesity and related diseases.
Interleukin-1β
Interleukin-1β (IL-1β) is a pro-inflammatory cytokine
expressed and secreted by AT.77 This cytokine is involved in
inflammatory processes responsible of pancreatic beta cells
destruction occurring in type diabetes 1.78
Adipokines and obesity and diabetes related diseases 
Hypertension
Adiponectin levels are lower in patients with arterial hyperten-
sion than in normotensive patients. Therefore, the increased levels
of this molecule appear to correlate with a reduced of the risk of
hypertension. Adiponectin is an important biological modulator of
vascular remodeling related to obesity and vascular disorders. This
molecule regulates blood pressure through mechanisms mediated
by the nervous system and endothelium.79,80 In vitro studies have
shown that it reduces the proliferation of smooth muscle cells and
inhibits the expression and the biological effects of TNF-α in
macrophages, thus reducing their molecular adhesion and transfor-
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mation into foamy cells.81 The anti-atherogenic properties of
adiponectin are mainly due to the production of Nitric Oxide (NO)
in endothelial cells79,80 which induces relaxation of blood vessels
relaxation and exerts anti- inflammatory and antithrombotic effects
on the blood vessel walls.82
Chronic kidney disease
Chronic kidney pathologies and the related functional and
structural changes of this organ caused by glomerulomegaly,
glomerulosclerosis, diabetic nephropathy, renal carcinoma,
nephrolithiasis, are related to obesity. Although endothelial dys-
functions are recognized as the pathogenetic mechanism of chronic
kidney diseases, some adipokines such as leptin, proinflammatory
cytokines and adiponectin can also contribute to kidney disfunc-
tions. In addition, weight loss and decreased apodiponectin levels
may hinder the progression of kidney damage.83,84 However, the
mechanisms responsible for the increased adiponectin levels
observed in presence of kidney damage and the clinical signifi-
cance of this phenomenon remain controversial. Further investiga-
tion are needed to better clarify these mechanisms.85
Visfatin/nampt is also implicated in chronic renal pathologies. In
particular, visfatin/nampt levels have been shown to be positively
associated with some circulating markers of endothelial dysfunc-
tion including Vascular Cell Adhesion Protein-1 (VCAM-1),
Intracellular Adhesion Protein -1 (ICAM- 1), Melanoma Cell
Adhesion Molecule-1 (MCAM-1).86,87 Conversely visfatin/nampt
levels were inversely associated with the rate endothelial function
expressed as brachial artery flow-mediated dilation or as rate of
glomerular filtration rate.88,89
Diabetic retinopathy
Diabetic retinopathy is one of the most frequent microvascular
complications, affecting 30-50% of diabetic patients.90 Adiponectin
levels were decreased in obese subjects and type 2 diabetes patients.
In the latter case the levels of circulating adiponectin resulted lower
in presence of diabetic retinopathy as compared to patients without
retinopathy.91 Furthermore, a positive correlation was observed
between low plasma levels of adiponectin and severity of diabetic
retinopathy.92 In patients with proliferative diabetic retinopathy,
Vascular Endothelial Growth Factor (VEGF) and adiponectin levels
were significantly more elevated in the aqueous humor than in the
control group.93,94 This phenomenon could be due to either an
increased permeability of the blood-retinal barrier or to the local
reparative process of endothelial dysfunction. Adiponectin induces
endothelial production of NO in vitro.95 The administration of the
angiogenesis inhibitor bevacizumab, may significantly reduce
VEGF and adiponectin levels.
Dyslipidemia
The term dyslipidemia refers to an abnormal increase in lipids
(cholesterol and triglycerides) in the blood. Dyslipidemia is often
associated with obesity and is a well known risk factor for cardio-
vascular disease. Obesity related dyslipidemia is mainly character-
ized by increased plasma levels of Free Fatty Acids (FFA) and
Triglycerides (TG), decreased levels of High Density Lipoproteins
(HDL) and an abnormal Low Density Lipoproteins (LDL) compo-
sition.21 An increased release of FFAs by adipose tissue can result
a increased FFAs uptake from the liver. This effect, in turn, deter-
mines an enhanced release of TG from the liver associated with an
increased production of Very-Low-Density Lipoproteins (VLDL),
and inhibition of Lipoprotein-Lipase (LPL) in adipose tissue and
skeletal muscle. These effects, in turn, give rise to hypertriglyc-
eridemia. In addition, the increase of VLDL from liver can inhibit
lipolysis of chylomicrons, thus contributing to the increase of plas-
ma TGs. TGs of VLDL are exchanged with Cholesterol Esters
(CE) from LDL and HDL from Cholesteryl Ester Transfer Protein
(CETP), producing TG rich LDL and HDL. LDL and HDL of TGs
are then hydrolyzed by the liver lipase, producing small and dense
LDL and HDL. The decrease in HDL concentrations and the syn-
thesis of small and dense LDL have been associated with an
increase in cardiovascular risk.21 On the other hand, a correlation
between dyslipidemia and amount of visceral adipose tissue has
been observed in patients with type 2 diabetes.96 The onset of dys-
lipidemia is also influenced by inflammatory molecules released
by adipose tissue, such as TNF-α, IL-6, IL-1, Amyloid Serum A
(SAA) and adiponectins. In obese patients, the presence of infil-
trating macrophages in adipose tissue is positively correlated with
circulating TG levels, while it is inversely correlated with plasma
HDL cholesterol levels.97 Circulating TNF-α levels are increased
in hyperlypidemic patients and correlate positively with VLDL
concentrations.98 TNF-α and IL-6 levels are increased in subjects
with hypertriglyceridemia.99,100 TG plasma levels remain elevated
in the presence of increased levels of anti-inflammatory cytokines,
such as IL-10.101 In healthy subjects and in subjects with cardio-
vascular diseases, proinflammatory cytokines, such as TNF-α, IL-
6 and IL-1, promote the increase in circulating levels of total cho-
lesterol and LDL-cholesterol, by activating the cholesterol synthe-
sis. These cytokines result also negatively associated with serum
cholesterol-HDL levels.102-104 However, a positive correlation was
found between the concentrations of the anti-inflammatory
cytokine IL-10 and HDL cholesterol plasma levels while, a nega-
tive correlation between IL-10 levels and high levels of total cho-
lesterol and LDL cholesterol was noted.101 Adiponectin has bene-
ficial effects on lipid metabolism105 and insulin sensitivity, as it
stimulates fatty acids oxidation and the use of glucose through the
activation of AMPK in the liver and muscle skeletal.106
Furthermore, plasma adiponectin levels negatively correlated with
TG levels while they positively correlated with HDL cholesterol
levels.107 On the other hand, decreased levels of adiponectin have
been shown to be associated with dyslipidaemias and cardiovascu-
lar disease.108,109 Recent studies have suggested the decrease of
adiponectin levels in the blood as a useful marker for dyslipi-
daemias in subjects with polycystic ovary syndrome being at
increased risk of dyslipidemia.110
Non alcoholic liver steatosis
Non-alcoholic liver steatosis (Non-Alcoholic Liver Disease,
NAFLD) is the most common form of chronic liver inflammation
and it is related to obesity.111-113 The development of NAFLD is
characterized by two phases: the first phase is characterized by
hepatic steatosis (accumulation of TG in the liver), followed in the
second phase, which is associated with inflammation and fibrosis
(Non-Alcoholic Steatohepatitis, NASH).113 The development of
NAFLD and its progression to NASH are explained by the “two
hits” hypothesis. According to this hypothesis, the “first hit” foster
the accumulation of lipids in the liver, while the “second hit”, caus-
es hepatocytes damage, inflammation and fibrosis,113 as a conse-
quence of the release of proinflammatory cytokines, adipokines,
mitochondrial dysfunctions, oxidative stress and lipid peroxidation.
The “two hits” hypothesis has been renamed “multi-hits” hypothe-
sis. This following the discovery of the contribute of various factors
in the development of NAFLD, such as lipid dysfunction, imbal-
ance of adipokines, inflammation in the AT, oxidative stress and
insulin resistance.114,115 In the “multi-hit” hypothesis, the imbalance
between lipid metabolism and insulin resistance is considered as










“first-hit”. Insulin resistance induced by hyperinsulinemia, causes
liver steatosis by increasing de novo liver lipogenesis, FFA efflux
from the AT due to increased lipolysis, by decreasing liver oxida-
tion and reducing VLDL secretion. Following the onset of steatosis,
the liver becomes more vulnerable to “multi-hit” factors, including
bacterial toxins derived from the intestine, cytokine/adipokine
imbalance, mitochondrial dysfunction, oxidative damage, unbal-
anced apoptosis in hepatocytes, release of pro-fibrogenic factors
and inflammatory mediators from damaged organelles and activa-
tion of Kupffer cells. These factors contribute to stimulating inflam-
mation, apoptosis, fibrosis, which lead to liver diseases
progression.116,117 In obese patients, the pro-inflammatory and anti-
inflammatory factors secreted by the AT are associated with
NAFLD.118 In particular, it has been suggested that adiponectin
possess anti-inflammatory activity, which may protect from hepatic
steatosis and inflammation, and that, in the liver, it increases the
suppressive activity of insulin on glucose production.119 The circu-
lating levels of adiponectin are lower in subjects with NAFLD than
in healthy subjects120 and are inversely correlated with biomarkers
of normal liver function in healthy subjects.121 On the other hand a
low level of adiponectin is a marker of liver steatosis and increase
the levels of enzymes characterizing liver damage in obese
subjects.122 Furthermore, in patients with NASH there is a reduc-
tion in the expression of adiponectin and its associated receptor
AdipoR2 compared to patients with steatosis alone.123
Leptin is also involved in NAFLD, as it directly stimulates
AMPK, which is involved in the activation of lipid oxidation (β-
oxidation and glycolysis) and in the inhibition of lipogenesis.124
There is a negative correlation between serum leptin levels and
liver damage in humans125 and a positive correlation between
serum leptin levels and elevated serum ALT levels or hepatic
steatosis. These effects has been shown to be independent from
body mass index or body fat mass index.126,127 Furthermore, in ani-
mal models while leptin increases in the presence of liver fibrosis,
a decrease in its levels is correlated with a reduction in liver dam-
age.128 Moreover, leptin is a powerful mitogen and an inhibitor of
apoptosis of Kupffer cells.129
Studies carried out in experimental animals have highlighted
that resistin regulates glucose and lipid metabolism and that may
act as a mediator insulin resistance in the liver. Increased resistin
values are found in NAFLD patients130,131 and in NASH patients
compared to patients with pure steatosis. However, in humans, the
role of resistin is still not well known. Therefore, further study are
needed to unravel its functions TNF-α is involved in the early and
late stages of NAFLD in both in animals and humans. In particular
this cytokine appear to modulate the transition from NASH to
NAFLD.132-134
Adipokines and cardiovascular diseases
Cardiovascular Diseases (CVDs) are the largest cause of death
in the world. They are characterized by alteration of myocardial
contractility, inflammation, and vascular damage. These patholog-
ical conditions include, hypertension, atherosclerosis, endothelial
and myocardial cell dysfunctions. Risk factors for CVDs are
hypertension, cigarette smoking, type 2 diabetes, overweight,
hyperlipidemia, metabolic syndrome, and family history lifestyle
(unhealthy diet and lack of exercise).135 Adipokines also play an
important role in the pathogenesis of CVDs.136
Adiponectin
In the heart, adiponectin mediates its action through the pres-
ence of three receptors e.g., AdipoR1, AdipoR2 and T-cad-
herin.60,137-139 Adiponectin receptors are also expressed in
platelets, where they mediate the inhibiting effects of adiponectin
on collagen-induced aggregation.140 Adiponectin has anti-athero-
genic properties, as it suppresses cell adhesion to the vascular
endothelium and promotes angiogenesis.105 This peptide is also
endowed with anti-inflammatory properties, due to its ability in
suppressing NF-kB factor, thus hindering the development of ath-
erosclerosis. Adiponectin can also inhibit the conversion of
macrophages into foamy cells and decreases LDL.81 Adiponectin
can also play a role in cardiac remodeling, which consists in
thwarting i the extent of myocardial hypertrophy.141 In humans, the
plasma levels of adiponectin are inversely correlated with insulin
resistance and the severity of coronary artery disease.142 On the
other hand, no correlations between serum adiponectin levels and
risk of coronary heart disease have been reported. However, it has
been suggested that the lack of correlation might be probably due
to the different adiponectin oligomers tested.143 However,
increased adiponectin levels are correlated with a reduction in the
risk of myocardial infarction in humans144 and with a lower risk of
coronary heart disease in diabetic patients.145 However, unlike it
may be expected, the circulating levels of this protein decreased
after a myocardial infarction.146 These findings indicate that
adiponectin has a beneficial role in cardiovascular pathologies and
atherosclerosis.
Leptin 
Leptin is is not exclusively produced by adipocytes but also by
cardiomyocytes and Smooth Muscle Vascular Cells (VSMC).147,148
Leptin and its receptors have been detected in cardiomyocytes,149
in VSMC,150 in endothelial cells,151 in the myometrium152 and in
cerebral and coronary vessels.153,154 Humans hyperleptinemia is
associated with atherosclerosis, hypertension and metabolic syn-
drome. In particular, this hormone has been shown to play an
important role in the early stages of atherosclerosis development,
and, in particular, during the recruitment of leukocytes and
macrophages in the endothelial wall.155 In humans, increased
serum leptin levels are associated with an increased risk of
myocardial infarction and stroke, which is independent from obe-
sity and cardiovascular risk factors.156 These effects have been, in
part, explained with the ability of leptin to increase insulin resist-
ance, to alter hemostasis balance and to induce vascular inflamma-
tion.157 Besides its proinflammatory properties, leptin possesses
pro-atherogenic properties. In fact this molecule has been reported
to promote i) production of proliferative and profibrinotic
cytokines, ii) to induces oxidative stress through Reactive Oxygen
Species (ROS) generation,158 iii) to stimulate cardiomyocyte
hypertrophy159 and VSMCs proliferation, iv) to stimulate platelet
aggregation and v) to increase the expression of pro-atherogenic
lipoprotein lipase.160 On the other hand, there are conflicting
results on the role of leptin in CVDs. While some of these studies
find a positive association between leptin concentration and hyper-
tension,161 other studies have highlighted a significant vasodilator
effect induced by leptin in coronary heart disease.162 Leptin con-
tributes to the development of obesity-related hypertension by
increasing the secretion of pro-inflammatory cytokines such as
TNF-α and IL-6, and by generating ROS in endothelial cells.155,158
Increased leptin levels have been reported to be also associated
with hypertension. Various mechanisms such as activation of the
renin-angiotensin system, hyperactivity of the sympathetic nerv-
ous system, endothelial dysfunction and reduction of the effect of
renal pressure on elimination may be involved in this
phenomenon.163 The heart itself produces leptin, which can act
locally to induce its physiological effects.164,165 Leptin has a nega-
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tive inotropic effect mediated by NO166 and regulates cardiac con-
tractility,167 size of cardiomyocytes and production extracellular
matrix components.168 Leptin has been also indicated to have ben-
eficial effects, such as reduction of lipid toxicity on the heart,169
protection of cardiomyocytes from the hypoxia-induced dam-
ages170 and myocardial remodelling.171 The protective effects of
leptin from damages induced by ischemia is further supported by
the “obesity paradox”, i.e., the unexpected reduction of co-morbid-
ity and mortality associated with cardiovascular diseases in sub-
jects with high body mass index.165
Resistin
Elevated plasma levels of resistin are correlated with pro-
atherogenic inflammatory markers,172 increased cardiovascular
risk, unstable angina, adverse prognosis of coronary diseases and
metabolic syndrome.173,174 Resistin has a pro-inflammatory role in
atherosclerosis, as it induces the expression of VCAM-1 and
Intercellular Adhesion Molecule-1 (ICAM-1),175 increases the
expression of proinflammatory cytokines (IL-1, IL-6, IL-12, TNF-
α);176,177 and the release of endothelin-1. In line with these obser-
vations, studies on atherosclerosis carried out in experimental ani-
mal models, have shown that resistin levels correlated with the
severity of the sclerotic lesion.178 In addition, the action of resistin
is inhibited by adiponectin.175
Visfatin
Visfatin is mainly produced and secreted in visceral fat.
However, it is also present in perivascular and epicardial adipose
tissue.179,180 Visfatin expression is positively associated with lipid
metabolism and atherosclerosis.181 In particular, it has been shown
that this molecule plays a role in the destabilization of atheroscle-
rotic plaques182 and inflammation. Consistent with these observa-
tions high levels of visfatin have been reported to induce the
expression of VCAM-1 and ICAM-1, and to increase the expres-
sion of pro-inflammatory cytokines.183 On the other hand, plasma
visfatin levels result inversely correlated with vascular endothelial
functions.184 However, visfatin has been reported to exert benefi-
cial effects. For instance, this hormone stimulates endothelial pro-
liferation and capillary formation in human endothelial cells,185
reduces apoptosis in human VSMCs.186 Furthermore, experimental
studies have shown that in rats, it reduces cardiac contractility and
induces vasodilatation mediated by NO produced by the endothe-
lium.187 In an in vivo ischemia-reperfusion models, a single i.v.
push of visfatin has been shown to reduce the size of the infarcted
area by 50% and to protect from the damage due to reoxygenation
of the cardiomyocytes.188-190 In patients with coronary artery dis-
ease and acute myocardial infarction, visfatin levels are positively
associated with unstable atherosclerotic lesions. Furthermore, vis-
fatin promotes destabilization of plaques and their rupture in dif-
ferent types of acute coronary syndromes.182 This molecule
appears to play also a role in both atherosclerosis and endothelial
dysfunctions.191 In vitro studies and in vivo studies suggest that
visfatin may have a neuroprotective role towards cerebral venous
thrombosis ischemia.192 Overall, visfatin can help to exacerbate
angiogenesis caused by ischemic heart disease, diabetes or athero-
sclerosis, and could, therefore, be considered a new target for more
effective treatments of these pathological conditions.191
Apelin
Apelin is a peptide produced and secreted by adipocytes, vas-
cular stroma and cardiovascular tissues.193 Apelin is expressed in
endothelial cells of the endocardium while, its receptor APJ is
expressed in cardiomyocytes. This suggest that the apelin system
acts on the heart by increasing cardiac contractility and heart
rate.194-196 Plasma apelin levels are positively associated with body
mass index and obesity, which is considered one of the major caus-
es of CVDs.197 On the other hand, decreased apelin levels are
observed in patients with atrial fibrillation not associated with
other CVDs198 and chronic heart damage.199 Overall, apelin is cur-
rently considered an adiponectin with a favorable effect for CVDs,
as it reduces atherogenesis, macrophage activity, cardiomyocyte
contractility, atrial fibrillation and heart damage. However, further
studies are needed to clearly outline its role in different myocardial
pathologies.136
Omentin
Omentin is an adipocytokine that is abundantly expressed in
the adipocytes present in the vascular stroma. It has anti-inflamma-
tory, anti-atherogenic and anti-diabetic properties.200 Omentin
plays an important role in the pathogenesis of vascular coronary
diseases, mainly in coronary artery atherosclerosis.201 Studies
undertaken in mice have shown that omentin promotes cellular
endothelial functions and revascularization in response to
ischemia.202 Serum omentin levels are lower in patients with acute
coronary syndrome or with stable angina pectoris than in healthy
subjects.203 Omentine could be a potential biomarker to predict the
development and progression of coronary heart disease in patients
with metabolic syndrome.204
Chemerin
Chemerine is a relatively recent adipokine. Its cardiovascular
properties have still not well established. Chemerin plasma levels
are positively correlated with the metabolic syndrome and associ-
ated risk factors, such as body mass index, hypertension and hyper-
triglycaeridemia205 Chemerin levels are increased in patients with
severe obesity.206 This adipokine appears to reduce inflammation
in endothelial cells by inducing NO synthesis which, in turn,
inhibits VCAM-1 mediated TNF-α induction and the consequent
lymphocyte adhesion through the suppression of the activation of
the NF-kB factor and that of the p38 signaling pathway.207 It also
promotes endothelial angiogenesis and the production and activity
of matrix metalloproteinases208 while reduces adhesion to endothe-
lial walls207 and enhances the contractile response to phenylepi-
nephrine in VSCMs and in the endothelium.209
Adipokines and gestational diabetes mellitus 
Gestational Diabetes Mellitus (GDM), is a frequent complica-
tion of pregnancy that can cause considerable risks to the mother
and the fetus.210 Untreated GDM, can progress to type 2 dia-
betes.211 GDM occurs in 3-7% of pregnancies212 and mostly in the
second trimester of pregnancy, due to the increased insulin resist-
ance and decreased function of pancreatic beta cells.213 Normally,
β-cells adapt to insulin demands for a given physiological con-
text.214 Following proliferative stimuli mediated by Placental
Lactogen Hormone (HPL), prolactin and growth hormone, these
cells increases up to 50% during pregnancy.215 During pregnancy,
selected insulin requirements in women are due to insulin resist-
ance, which is related to HPL production, food intake, body weight
intake, and to the fetal presence itself.216,217 GDM increases the
risk of developing type 2 diabetes and/or that of other complica-
tions in pregnancy, such as pre-eclampsia. These conditions may
increase the possibility to resort to cesarean section and complica-
tions in problems, such as macrosomia. Children born from moth-










2 diabetes mellitus as adults, as well as hypoglycemia, hypocal-
caemia, polycythemia, jaundice and respiratory distress syn-
dromes.213 Serum adiponectin levels progressively decrease during
pregnancy.218,219 In women with GDM, the increased secretion of
inflammatory cytokine could reduce the secretion of adiponectin,
whose excessive low levels contribute to insulin resistance.
Adiponectin may be considered a factor related to insulin resist-
ance and pancreatic beta cell dysfunction in the pathogenesis of
type 2 diabetes.214-216,220 Leptin is also secreted by the placenta. It
regulates the secretion of Gonadotropin Releasing Hormone
(GnRH) and activates the orthosympathetic nervous system. In
normal pregnancy, leptin concentrations are 2-3 times higher than
in non-pregnant subjects and peaks around the 28th week of gesta-
tion. Leptin has a potential role in embryo implantation, in the
induction of the secretion of human chorionic gonadotropin, in the
formation of trophoblastic cells and in the regulation of placenta
growth. Furthermore, Leptin increases mitosis and promotes the
absorption of amino acids.220 The expression of leptin in the pla-
centa is increased in pregnant women with GDM, compared to
women with a normal pregnancy.220 This could be explained with
the presence of hyperinsulinemia in GDM.220,221
Discussion and conclusions
Adipokines are currently considered an exciting new link
between obesity and insulin resistance, obesity and cardiovascular
disease and hypertension and hyperlipidemia. Although the influ-
ence of adipokine on obesity in pathological conditions associated
with obesity and metabolism has been well established, this phe-
nomenon have been investigated more in detail. This review analy-
ses and discuss the current findings of these studies. In general,
adipokines can increase or decrease insulin sensitivity and can
influence appetite and food intake.6 The increased knowledge from
studies on physiological and pathological functions of new
adipokines suggests that adiponectin, visfatin, vaspin and omentin
may also improve the effects of insulin.55,56,200 Various studies have
contributed to greatly increase our knowledge about the physiolog-
ical functions of adiponectin. These studies have shown that elevat-
ed plasma levels of adiponectin are associated with a lower inci-
dence of type 2 diabetes mellitus and that reduced expression levels
of this this protein can be observed in insulin resistance.16
Unfortunately, the clinical studies undertaken so far, has failed to
highlight a direct sensitizing effect of adiponectin on endogenous
insulin. However, preclinical in vivo studies have suggested that
adiponectin, adiponectin receptor agonists and AMPK activators
may be good candidates for developing new therapeutic options for
the clinical management of type 2 diabetes and obese patients.64
Furthermore, drugs that increase the expression of anti-inflammato-
ry adiponectin in fats are also of potential interest. Other com-
pounds including combined PPAR/PPAR-agonist could also medi-
ate some of their effects on insulin sensitivity through similar mech-
anisms. On the other hand, the role of Visfatin, Vaspin and Omentin
in human insulin resistance and obesity needs to be better clarified
to define their therapeutic potential. Regarding the adipokine
induce insulin resistance, the role of IL-6 in human insulin sensitiv-
ity and obesity is the best understood.24,25 IL-6 increases glucose
tolerance in vivo. Moreover, elevated baseline IL-6 levels are asso-
ciated with an increased risk of developing a reduced glucose toler-
ance.26 However, therapeutic approaches based on direct inhibition
of IL-6 should not probably be feasible in the clinical practice, due
to various expected side effects. TNFα and resistin appear as the
main links between insulin resistance and obesity in rodents.
However, their role in humans remain still uncertain.15 In addition,
clinical observations haves shown that the inhibition of TNFα has
no effect on insulin sensitivity. Clinical studies on the physiological
role PAI-1, SPARC/osteonectin, MCP-1 and RBP-4 are scanty so
their role in insulin resistance and obesity, is still not well delineat-
ed. Leptin is the main appetite suppressant hormone. This adipokine
is very effective in human leptin deficiency. However, the knowl-
edge of mechanisms mediating leptin resistance in obesity it is of
pivotal importance to find new therapeutic options to replenish cen-
tral and peripheral leptin signaling. The results from numerous
experimental and clinical studies reported in this review, highlight
that various adipokines can be regarded as potential targets in the
treatment of insulin resistance and obesity and related metabolic
pathologies. It is now well established that the altered expression
and secretion of adipokines, which occurs in obesity, especially in
the visceral obesity, determines important circulatory and metabolic
alterations. However, among the numerous signaling molecules and
their associated effects identified by these investigations, those with
potential clinical interest that might undergo to pharmacological
modulation have to be still identified. Ultimately, advances in the
knowledge of adipocyte biology may lead to a better understanding
of the physiological functions attributed to the adipose tissue which,
now is currently considered multi-functional organ rather than sim-
ply a passive storage site for excess energy.
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